Clinical trial · Observational
The Identification of Novel Prognostic Markers in Melanoma
Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples
NCT01002560CI-TRIAL-00002735unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Melanoma | Melanoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Malignant melanoma tumour tissue
- label
- Benign pigmented lesions & other skin cancers
- description
- Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
Primary outcomes (1)
- measure
- Given that the nature of the research is qualitative, there is no primary outcome measure.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of melanoma * Adequate paraffin-embedded material available for analysis. * Adequate clinical follow-up information * Written informed consent where applicable Exclusion Criteria: * Inadequate paraffin-embedded material available * Inadequate clinical follow-up information.
References
Publications (0)
Data not yet available
No reference posted for this study.